Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Sponsor:
- ImmunityBio, Inc.
- Sponsor Study ID:
- ResQ201A-NSCLC
- CTO #:
- 104196
- NCT Number:
- NCT06745908
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Lung
- Study Objectives:
- Compare OS between the experimental and control arms. Compare immune DCR (iDCR), immune progression-free survival (iPFS), immune overall response rate (iORR), and immune duration of response (iDOR) as measured using immune Response Evaluation Criteria in Solid Tumors (iRECIST) between the experimental and control arms.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Alexander, Mariam, at alexanma@musc.edu .
- Study Coordinator, Morgan, Shelby, at morshelb@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina